

Resource Summary Report

Generated by [RRID](#) on Aug 2, 2026

Agilent Technologies

RRID:SCR_013575

Type: Tool

Proper Citation

Agilent Technologies (RRID:SCR_013575)

Resource Information

URL: <http://www.agilent.com/>

Proper Citation: Agilent Technologies (RRID:SCR_013575)

Description: Company provides laboratories worldwide with analytical instruments and supplies, clinical and diagnostic testing services, consumables, applications and expertise in life sciences and applied chemical markets.

Resource Type: commercial organization, antibody supplier, reagent supplier, material resource

Keywords: instrument, service, software, supply, expertise, life science, clinical, diagnostic, testing, reagent, market,

Resource Name: Agilent Technologies

Resource ID: SCR_013575

Alternate IDs: nlx_152258

Record Creation Time: 20220129T080316+0000

Record Last Update: 20260801T190450+0000

Ratings and Alerts

No rating or validation information has been found for Agilent Technologies.

No alerts have been found for Agilent Technologies.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 45936 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Monteiro AC, et al. (2026) OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer. *Cancer research communications*, 6(1), 85.

Yousefi R, et al. (2025) A microscopy-based screen identifies cellular kinases modulating mitochondrial translation. *Cell reports*, 44(1), 115143.

Markusson S, et al. (2025) Nanobodies against the myelin enzyme CNPase as tools for structural and functional studies. *Journal of neurochemistry*, 169(1), e16274.

Lal S, et al. (2025) Nanoparticle-formulated mRNA encoding engineered multivalent SIRP ?-Fc fusion proteins shows robust anti-cancer activity in preclinical models. *Molecular therapy. Nucleic acids*, 36(2), 102550.

Del Val E, et al. (2025) MyD88 polymerization and association to cellular membranes in a yeast heterologous model. *Cellular and molecular life sciences : CMLS*, 82(1), 288.

Noorani I, et al. (2025) Extrachromosomal DNA-Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma. *Cancer discovery*, 15(10), 2078.

Tesi B, et al. (2025) Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 3062.

Lee SM, et al. (2025) Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 848.

Klemm N, et al. (2025) The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative Effect. *Cancer research*, 85(11), 1978.

Dar D, et al. (2025) Imaging PD-L1 in the brain-Journey from the lab to the clinic. *Neuro-oncology*, 27(2), 567.

Liu M, et al. (2025) MiR-298 suppresses astrocytic NF-?B activity and neuroinflammation via targeting MyD88 in bone cancer pain. *The Korean journal of pain*, 38(3), 292.

Feiner N, et al. (2025) The genome sequence of the Dalmatian wall lizard, *Podarcis melisellensis* (Braun, 1877). *Wellcome open research*, 10, 247.

Askar AM, et al. (2025) Rapid GC-MS method for screening seized drugs in forensic investigations: optimization and validation. *Frontiers in chemistry*, 13, 1559279.

Ahmad I, et al. (2025) Gut Microbiota in a Viral Model of Multiple Sclerosis: Modulation and Pitfalls by Oral Antibiotic Treatment. *Cells*, 14(12).

De Oro-Carretero P, et al. (2025) Assessing Bioconcentration and Biotransformation of BDE-47 In Vitro: The Relevance of Bioavailable and Intracellular Concentrations. *Journal of xenobiotics*, 15(3).

Hefni ME, et al. (2025) Plasma TMAO Concentrations and Gut Microbiota Composition in Subjects with and Without Metabolic Syndrome: Results from Pilot Study. *Metabolites*, 15(6).

Javid M, et al. (2025) Metal Exposure, Bioaccumulation, and Toxicity Assessment in Sediments from the St. Lawrence River Before and After Remediation Using a Resuspension Technique. *Toxics*, 13(6).

Ji S, et al. (2025) Quantitative Detection of Micro- and Nanoplastics (>300 nm) in Human Urine Using Double-Shot Py-GC/MS with Internal Standard Calibration. *Toxics*, 13(6).

Martín Cruz B, et al. (2025) Widespread Contamination by Anticoagulant Rodenticides in Insectivorous Wildlife from the Canary Islands: Exploring Alternative Routes of Exposure. *Toxics*, 13(6).

Abera A, et al. (2025) Genomic Characterization of *Leishmania tropica* in Cutaneous Leishmaniasis, Somali Region, Ethiopia, 2023. *Emerging infectious diseases*, 31(7), 1483.